JPWO2020065402A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065402A5 JPWO2020065402A5 JP2021516886A JP2021516886A JPWO2020065402A5 JP WO2020065402 A5 JPWO2020065402 A5 JP WO2020065402A5 JP 2021516886 A JP2021516886 A JP 2021516886A JP 2021516886 A JP2021516886 A JP 2021516886A JP WO2020065402 A5 JPWO2020065402 A5 JP WO2020065402A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- administration
- particulate matter
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- 108010023302 HDL Cholesterol Proteins 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 229960005135 Eicosapentaenoic Acid Drugs 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N Eicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 3
- 108009000578 Oxidative Stress Proteins 0.000 claims 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 102100001085 APOB Human genes 0.000 claims 2
- 101700065507 APOB Proteins 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 2
- 108010055292 Chemokine CCL2 Proteins 0.000 claims 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 229940100601 Interleukin-6 Drugs 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 238000003915 air pollution Methods 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N 9α,11α-PGF2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims 1
- 206010003119 Arrhythmia Diseases 0.000 claims 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N Ethyl eicosapentaenoic acid Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 229940118019 Malondialdehyde Drugs 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 229940012843 Omega-3 Fatty Acids Drugs 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 102100019577 VCAM1 Human genes 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000003859 lipid peroxidation Effects 0.000 claims 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (18)
- 対象における大気汚染への長期および／または短期の曝露によって誘発される酸化ストレス、内皮機能障害、動脈の狭窄および／もしくは肥厚、ならびに／または炎症を治療または予防するための組成物であって、前記対象に１日あたりに投与するための約４ｇのエイコサペンタエン酸を含む組成物。
- 前記大気汚染が、粒子状物質を含む、請求項１に記載の組成物。
- 対象における粒子状物質の吸入によって誘発される酸化ストレス、内皮機能不全、動脈の狭窄および／もしくは肥厚、ならびに／または炎症を治療または予防するための組成物であって、前記対象に１日あたりに投与するための約４ｇのエイコサペンタエン酸を含む組成物。
- 対象における粒子状物質の吸入によって誘発される酸化ストレス、内皮機能不全、動脈の狭窄および／もしくは肥厚、ならびに／または炎症を治療または予防し、かつ前記対象におけるアテローム性動脈硬化症の心血管疾患のリスクを減少させるための組成物であって、前記対象に１日あたりに投与するの約４ｇのエイコサペンタエン酸を含む組成物。
- 前記粒子状物質が、直径約１０μｍ未満かつ約２．５μｍ超である、請求項２～４のいずれか一項に記載の組成物。
- 前記粒子状物質が、直径約２．５μｍ以下である、請求項２～４のいずれか一項に記載の組成物。
- 前記粒子状物質が、直径約０．１μｍ未満である、請求項２～４のいずれか一項に記載の組成物。
- 前記炎症が、肺および／または全身性炎症である、請求項１～７のいずれか一項に記載の組成物。
- 前記組成物の投与が、前記対象におけるアテローム性動脈硬化症の心血管疾患のリスクを減少させる、請求項１～８のいずれか一項に記載の組成物。
- 前記対象が、血圧レベルの減少を経験する、請求項１～９のいずれか一項に記載の組成物。
- 前記対象が、インスリン抵抗性の減少を経験する、請求項１～１０のいずれか一項に記載の組成物。
- 前記組成物の投与が、前記対象における、血管内皮増殖因子（ＶＥＧＦ）、腫瘍壊死因子－α（ＴＮＦ－α）、単球走化性タンパク質－１（ＭＣＰ－１）、インターロイキン－１β（ＩＬ－１β）、可溶性細胞間接着分子－１（ｓＩＣＡＭ－１）、可溶性血管細胞接着分子－１（ｓＶＣＡＭ－１）、高感度反応性タンパク質（ｈｓＣＲＰ）、リポタンパク質関連ホスホリパーゼＡ２（Ｌｐ－ＰＬＡ２）、および循環単球レベルからなる群から選択される炎症性バイオマーカーを減少させる、請求項１～１１のいずれか一項に記載の組成物。
- 前記組成物の投与が、前記対象における、総コレステロール（ＴＣ）、超低密度リポタンパク質コレステロール（ＶＬＤＬ－Ｃ）、低密度リポタンパク質コレステロール（ＬＤＬ－Ｃ）、高密度リポタンパク質コレステロール（ＨＤＬ－Ｃ）、非高密度リポタンパク質コレステロール（非ＨＤＬ－Ｃ）、ＨＤＬ－Ｃ機能性、アポリポタンパク質Ｂ（ＡｐｏＢ）、インターロイキン－６（ＩＬ－６）、アポリポタンパク質Ａ－１（ＡｐｏＡ－１）、およびインスリン抵抗のホメオスタシスモデル評価（ＨＯＭＡ－ＩＲ）レベルからなる群から選択される代謝バイオマーカーを減少させる、請求項１～１２のいずれか一項に記載の組成物。
- 前記組成物の投与が、前記対象における、脂質酸化、脂質過酸化、脂質ヒドロ過酸化、マロンジアルデヒド、プロスタグランジンＦ－２α（ＰＧＦ－２α）、血小板由来増殖因子（ＰＤＧＦ）、および抗酸化能レベルからなる群から選択される酸化バイオマーカーの減少を経験する、請求項１～１３のいずれか一項に記載の組成物。
- 前記組成物の投与が、前記対象の心拍数および／または心臓リズムにおいて有益な効果を示す、請求項１～１４のいずれか一項に記載の組成物。
- 前記有益な効果が、不整脈抑制レベル、心室性不整脈率もしくは心拍数の減少、または心拍数変動性の増加を含む、請求項１５に記載の組成物。
- 前記組成物が、１日あたり１～４用量単位で前記対象に投与される、請求項１～１６のいずれか一項に記載の組成物。
- エイコサペンタエン酸エチルエステルが、前記組成物中のすべてのオメガ－３脂肪酸の少なくとも約９６重量％を構成する、請求項１～１７のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736897P | 2018-09-26 | 2018-09-26 | |
| US62/736,897 | 2018-09-26 | ||
| PCT/IB2019/001059 WO2020065402A1 (en) | 2018-09-26 | 2019-09-25 | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502401A JP2022502401A (ja) | 2022-01-11 |
| JPWO2020065402A5 true JPWO2020065402A5 (ja) | 2022-09-30 |
Family
ID=68387354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516886A Pending JP2022502401A (ja) | 2018-09-26 | 2019-09-25 | 大気汚染への曝露に起因する疾病および／または障害を治療または予防するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210330624A1 (ja) |
| EP (1) | EP3856171A1 (ja) |
| JP (1) | JP2022502401A (ja) |
| KR (1) | KR20210066831A (ja) |
| CN (1) | CN113164426A (ja) |
| AU (1) | AU2019346108A1 (ja) |
| BR (1) | BR112021005813A2 (ja) |
| CA (1) | CA3113177A1 (ja) |
| MX (1) | MX2021003264A (ja) |
| PH (1) | PH12021550698A1 (ja) |
| TW (1) | TW202027737A (ja) |
| WO (1) | WO2020065402A1 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
| DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
| RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CA3217098A1 (en) * | 2021-04-29 | 2022-11-03 | Richard Louis Dunbar | Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject |
| CN113384568B (zh) * | 2021-06-04 | 2022-11-15 | 广东工业大学 | 预防和/或修复大气污染导致的心脏损伤的联合用药物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172818B2 (en) * | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| BR112017012810A2 (pt) * | 2014-12-15 | 2018-04-10 | Dsm Ip Assets B.V. | método para tratamento ou prevenção de doenças associadas à poluição do ar |
-
2019
- 2019-09-25 EP EP19795317.7A patent/EP3856171A1/en active Pending
- 2019-09-25 JP JP2021516886A patent/JP2022502401A/ja active Pending
- 2019-09-25 CN CN201980077903.0A patent/CN113164426A/zh active Pending
- 2019-09-25 CA CA3113177A patent/CA3113177A1/en active Pending
- 2019-09-25 MX MX2021003264A patent/MX2021003264A/es unknown
- 2019-09-25 US US17/280,092 patent/US20210330624A1/en active Pending
- 2019-09-25 KR KR1020217010564A patent/KR20210066831A/ko unknown
- 2019-09-25 AU AU2019346108A patent/AU2019346108A1/en active Pending
- 2019-09-25 BR BR112021005813-3A patent/BR112021005813A2/pt not_active Application Discontinuation
- 2019-09-25 TW TW108134626A patent/TW202027737A/zh unknown
- 2019-09-25 WO PCT/IB2019/001059 patent/WO2020065402A1/en unknown
-
2021
- 2021-03-26 PH PH12021550698A patent/PH12021550698A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020065402A5 (ja) | ||
| Brennan et al. | Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function | |
| Juergens et al. | Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo | |
| Rupp et al. | Risk Stratification by the" EPA+ DHA Level" and the" EPA/AA Ratio" | |
| Othman et al. | Beyond cholesterol-lowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties | |
| US20210330624A1 (en) | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution | |
| Wallace et al. | Activation state alters the effect of dietary fatty acids on pro-inflammatory mediator production by murine macrophages | |
| EP0637957B1 (de) | Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen | |
| JP2006519244A (ja) | 糖尿病患者の治療におけるω−３−脂肪酸の使用 | |
| WO2018017667A1 (en) | Lipid formulations containing bioactive fatty acids and other bioactive agents | |
| JPWO2020037153A5 (ja) | ||
| AU2021201865A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| SK282308B6 (sk) | Použitie terpénov na výrobu farmaceutického prostriedku | |
| EP2099295A1 (en) | Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids | |
| Das | Molecular biochemical aspects of salt (sodium chloride) in inflammation and immune response with reference to hypertension and type 2 diabetes mellitus | |
| Palombo et al. | Cyclic vs Continuous Enteral Feeding With ω‐3 and γ‐Linolenic Fatty Acids: Effects on Modulation of Phospholipid Fatty Acids in Rat Lung and Liver Immune Cells | |
| US20040235948A1 (en) | Treatment of diabetic patients with omega-3-fatty acids | |
| Medeiros et al. | Long-term intake of edible oils benefits blood pressure and myocardial structure in spontaneously hypertensive rat (SHR) and streptozotocin diabetic SHR | |
| JPWO2012108379A1 (ja) | 拡張性うっ血性心不全治療剤 | |
| RU2021111609A (ru) | Композиции и способы лечения или предотвращения заболеваний и/или расстройств, вызванных воздействием загрязнения воздуха | |
| Nagai et al. | Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling | |
| JPS6045516A (ja) | １α―ヒドロキシビタミンＤ３類を含有することを特徴とする抗炎症解熱鎮痛剤 | |
| JP5952556B2 (ja) | 褥瘡治療剤 | |
| Mateos et al. | Eicosanoid synthesis and respiratory distres s syndrome in intensive medicine | |
| JPH04244023A (ja) | ω６系不飽和脂肪酸含有薬剤 |